| Not Yet Recruiting | Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy Primary Biliary Cholangitis | Phase 3 | 2026-03-01 |
| Not Yet Recruiting | Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Sarogl Primary Biliary Cholangitis | Phase 3 | 2026-02-01 |
| Active Not Recruiting | Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | 2025-09-17 |
| Recruiting | Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Dis Cholestatic Liver Disease | Phase 1 | 2025-08-05 |
| Recruiting | Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis Primary Biliary Cholangitis | Phase 3 | 2024-07-16 |
| Terminated | Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US Nonalcoholic Fatty Liver Disease | Phase 2 | 2022-12-08 |
| Completed | Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis Primary Biliary Cholangitis | Phase 2 / Phase 3 | 2022-04-01 |
| Recruiting | Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease | Phase 1 | 2021-10-21 |
| Completed | Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis Nonalcoholic Steatohepatitis, Fibrosis | Phase 2 | 2021-08-18 |
| Completed | A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Fu Renal Impairment | Phase 1 | 2020-07-27 |
| Completed | Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function Hepatic Impairment | Phase 1 | 2020-07-16 |
| Completed | Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subje Healthy | Phase 1 | 2019-09-20 |
| Completed | A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers Healthy | Phase 1 | 2019-08-19 |
| Completed | Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Non Alcoholic Steatohepatitis | Phase 2 | 2019-06-12 |
| Completed | Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fa Liver Transplant; Complications, NAFLD | Phase 2 | 2019-02-25 |
| Terminated | Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (E Non-alcoholic Fatty Liver Disease in Women With PCOS | Phase 2 | 2019-02-12 |
| Completed | Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholan Primary Biliary Cirrhosis | Phase 2 | 2017-08-18 |
| Suspended | Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 Dyslipidemias | Phase 2 | 2017-04-06 |
| Completed | Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | 2017-04-06 |